martes, 22 de septiembre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 16, 2026

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

View original at finance.yahoo.com

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Olema Oncology On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Commercial launch preparations are underway for a potential approval in late 2027
60% confidence
Top-line data from OPERA-01 is expected in the fall of 2026
60% confidence
Transformation into a fully-integrated oncology company is underway in preparation for the Company's first potential commercial launch in late 2027
60% confidence
Olema is on-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial
60% confidence
The November 2025 public offering enables funding operations through numerous expected value-creating events with palazestrant
60% confidence
Initial clinical results from OP-3136 are anticipated in Q2 2026
60% confidence
2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens
60% confidence
Palazestrant has potential as the combination endocrine therapy of choice in the metastatic setting
60% confidence

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets

Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.

Nuestra lectura de los datos ›

Señales que seguimos

Satellite-Terrestrial Network Integration Acceleration

Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,983

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,983 hechos verificados con la fuente5,304 documentos fuente archivados

Consulta estos datos → isubstrate.com

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results — Source | Via News | es.VIA.NEWS